clearclearclearclearclearclear

Antibody Validation

clearclearclearclearclearclearclearclearclearclearclearclearclearclearclearclearclear

Sort By:

Products (805)

page of 68

Primary Antibodies

Novus offers a wide range of primary antibody products. Find primary antibodies for your research and use the filters to easily sort our primary antibodies by species, applications and conjugates. Our primary antibodies are backed by the Novus Guarantee + Policy.

805 Results for "primary-antibodies"

NB100-2220

LC3B Antibody

(39 Reviews)

(774 Publications)

0.1 ml

NB100-2220

Knockout Validated: LC3B Antibody [NB100-2220] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and LC3B knockout HeLa cell line (KO) untreated (-) or treated (+) with 50 uM Chloroquine for 18 hours. PVDF membrane was probed with 0.5 ug/mL of Rabbit Anti-LC3B Monoclonal Antibody (Catalog # NB100-2220) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog# HAF008). A specific band was detected for LC3B at approximately 15 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. GAPDH is shown as a loading control. This experiment was conducted under reducing conditions.

<b>Genetic Strategies Validation. </b>Knockout Validated: LC3B Antibody [NB100-2220] - LC3B/MAP1 [NB100-2220] - Detection of LC3 in mouse ES cell lysates. Atg5-/- ES cells from Dr. Noboru Mizushima [Mizushima, N. et al. J. Cell Biol. 152 (2001)] Photo courtesy of Dr. Beth Levine, UT SW Medical Center.

<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody [NB100-2220] - LC3B/MAP1 [NB100-2220] - Western blot analysis of HeLa (1), HeLa + CQ (2), SHSY5Y (3), SHSY5Y +CQ (4), A431 (5), A431 +CQ (6) and Ntera2 (7) using LC3 antibody at 2 ug/ml.

<b>Genetic Strategies Validation. </b>Knockout Validated: LC3B Antibody [NB100-2220] - LC3 was detected in immersion fixed Cloroquine treated Hela cells (left) but was not detected in LC3 knockout Hela cells (right) using rabbit anti-human LC3 polyclonal antibody (Catalog #NB100-2220) at 0.3 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rabbit IgG Secondary Antibody (red; Catalog # NL004) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm.

<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody [NB100-2220] - shows lysates of mouse NIH3T3 and rat PC-12 cell lines untreated (-) or treated (+) with Chloroquine. PVDF membrane was probed with 0.5 ug/mL rabbit anti-LC3B polyclonal Antibody (NB100-2220, Novus Biologicals), followed by 1:2000 dilution of goat anti-rabbit IgG secondary antibody.

Western Blot: LC3B Antibody [NB100-2220] - Analysis of LC3 in Huh-7 and SMMC-7721 cells using anti-LC3B antibody. Image from verified customer review.

Western Blot: LC3B Antibody [NB100-2220] - Analysis using the Biotin conjugate of NB100-2220. Image from verified customer review.

Immunohistochemistry-Paraffin: LC3B Antibody [NB100-2220] - Human ovarian Cancer tissue stained using heat mediated antigen retrieval in pH 6.0 citrate buffer at 1:200 dilution. Image provided by verified customer review.

Immunocytochemistry/Immunofluorescence: LC3B Antibody [NB100-2220] - LC3B detected in immersion fixed HeLa human cervical epithelial carcinoma cell line treated with Chloroquine using 1ug/mL rabbit anti-LC3B polyclonal (NB100-2220, Novus Biologicals). Cells were stained using donkey anti-rabbit IgG-NL557 and counterstained with DAPI (blue).

Western Blot: LC3B Antibody [NB100-2220] - Autophagy Investigation. (A) Representative WBs of LC3B-I, LC3B-II and GAPDH loading control in DANs derived from 4 iPD patients and 4 healthy controls. (B) WBs from three independent experiments were quantified by densitometry and LC3B-II normalized to a loading control. Grouping of data by healthy vs iPD as well as iPD stratified for T/T and C/C genotype. (C) Ratio of LC3B-II (normalized to loading control) following bafilomycin treatment/untreated. Citation: Marrone L, Bus C, Schondorf D, Fitzgerald JC, Kubler M, Schmid B, et al. (2018) Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease. PLoS ONE 13(3): e0192497. //doi.org/10.1371/journal.pone.0192497

Immunocytochemistry/Immunofluorescence: LC3B Antibody [NB100-2220] - LC3 antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).

Immunohistochemistry: LC3B Antibody [NB100-2220] - Analysis using the Biotin conjugate of NB100-2220. Staining of brain, cerebral cortex, neurons with cell processes.

Western Blot: LC3B Antibody [NB100-2220] - Analysis of LC3 in H9C2 cells.

Western Blot: LC3B Antibody [NB100-2220] - Analysis using the DyLight 550 conjugate of NB100-2220. Detection of LC3 in pancreatic cancer cells.

Western Blot: LC3B Antibody [NB100-2220] - Detection of LC3 in mouse HL-1 cell lysate. Photo courtesy of product review by verified customer.

<b>Genetic Strategies Validation. </b>Western Blot: LC3B Antibody [NB100-2220] - WB detection of LC3I and LC3II in mouse cochlea cell line SV-K1. Cells were treated with chloroquine (1uM), and As2O3 (1uM) for 24 hrs. This image was submitted via customer review.

Western Blot: LC3B Antibody [NB100-2220] - Detection in fibroblast whole cell extract. Image from verified customer review.

Western Blot: LC3B Antibody [NB100-2220] - Macrophage lysates probed with anti-LC3 antibody. This image was submitted via customer Review.

Western Blot: LC3B Antibody [NB100-2220] - Uncropped western blots used for quantification. Detection of LC3B. Normalized Protein levels by the indicated housekeeping protein. iPD genotypes are reported. Blots show protein levels in the presence or absence of a specified treatment. Baf = bafilomycin, Rot = rotenone, Val = valinomycin, CZC = CZC-25146Citation: Marrone L, Bus C, Schondorf D, Fitzgerald JC, Kubler M, Schmid B, et al. (2018) Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease. PLoS ONE 13(3): e0192497. //doi.org/10.1371/journal.pone.0192497